Virtual Library

Start Your Search

T.Y. Takagaki



Author of

  • +

    P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P2.04-041 - Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma (ID 1596)

      09:30 - 09:30  |  Author(s): T.Y. Takagaki

      • Abstract
      • Slides

      Background:
      The presence of EGFR activating mutations in pulmonary adenocarcinoma is predictive of exquisite response to EGFR-tyrosine kinase inhibitors. Here we studied the frequency of EGFR activating mutations in pts consecutively treated in our institution.

      Methods:
      It is a retrospective, uniinstitutional study of all consecutively tested samples from pts diagnosed with pulmonary adenocarcinoma and treated in our Institute. All samples were formalin-fixed and paraffin-embedded. Tumor areas were selected and macrodissected, followed by whole DNA extraction and amplification by PCR. EGFR genotyping was performed through DNA sequencing (exons 18, 19, 20 and 21) by Sanger´s methodology.

      Results:
      417 pts had tumor samples genotyped between Aug/2011 and Sep/2015. Median age was 62 y (17-91), 237 (57%) female. According to ethnicity, 357 pts were Caucasian (86%), 37 African-American (9%) and 21 Asian (5%); 140 pts were classified as never-smokers (34%), 37 (9%) as light-smokers (≤ 10 p.y.) and 238 (57%) as current smokers/> 10 p.y.. EGFR activating mutations could be identified in 103 out of 417 samples (24.7%): 78 were exon 19 deletions (76%), 23 were L858R mutation in exon 21 (22%), and two were rare mutations (G719S in exon 18, and V774M and S768I in exon 20). These mutations were found to be more frequent in females than in males (32% vs. 15%, p=0.0001), and in never-smokers and light-smokers than in current smokers/> 10 p.y. (65% vs. 16%, p<0.0001). It is noteworthy to mention that EGFR mutations were detected in 31 current smokers/> 10 p.y. pts. With the exception of 2 cases, all tumors harboring EGFR activating mutations presented TTF-1 expression by immunohistochemistry, and among those TTF-1-negative adenocarcinomas, no mutation was detected in 36/38 samples (p=0.0011). In a median follow-up of 12 months, the median overall survival was 16.3 months among those pts with stage IV and ECOG-PS 0-1, whose tumors presented EGFR-activating mutations.

      Conclusion:
      In this Brazilian pts, the frequency of EGFR activating mutations was 28%, being more frequent in females, and never-smokers or light smokers. These results reinforce the importance of diagnosing EGFR activating mutations in all pts with TTF-1-positive, pulmonary adenocarcinoma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.